[ad_1]
NEW DELHI: Biocon Biologics, a subsidiary of Biocon, announced a five-year partnership with Sandoz AG providing it exclusive rights to promote, sell and distribute two biosimilars —Trastuzumab and Bevacizumab, in Australia, says a company statement.
Under the agreement, Sandoz will distribute the Biocon Biologics’ brands, OGIVRI (bTrastuzumab) and ABEVMY (bBevacizumab), and facilitate the sustained access of these medications that were previously distributed by another pharmaceutical company to patients in Australia.
Trastuzumab is a biosimilar of Herceptin and Bevacizumab is a biosimilar of Avastin.
The agreement is effective from January 1, 2024 and commercialisation commenced on February 1.
Under the agreement, Sandoz will distribute the Biocon Biologics’ brands, OGIVRI (bTrastuzumab) and ABEVMY (bBevacizumab), and facilitate the sustained access of these medications that were previously distributed by another pharmaceutical company to patients in Australia.
Trastuzumab is a biosimilar of Herceptin and Bevacizumab is a biosimilar of Avastin.
The agreement is effective from January 1, 2024 and commercialisation commenced on February 1.
#Biocon #Biologics #ties #Sandoz #biosimilars
